- Home
- NNAVW vs VCEL Comparison
NNAVW vs VCEL Comparison
Compare NNAVW & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNAVW
- VCEL
- Stock Information
- Founded
- NNAVW 2007
- VCEL 1989
- Country
- NNAVW United States
- VCEL United States
- Employees
- NNAVW 96
- VCEL N/A
- Industry
- NNAVW Industrial Machinery/Components
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NNAVW Industrials
- VCEL Health Care
- Exchange
- NNAVW Nasdaq
- VCEL Nasdaq
- Market Cap
- NNAVW N/A
- VCEL 2.1B
- IPO Year
- NNAVW N/A
- VCEL 1997
- Fundamental
- Price
- NNAVW $7.22
- VCEL $30.02
- Analyst Decision
- NNAVW
- VCEL Strong Buy
- Analyst Count
- NNAVW 0
- VCEL 6
- Target Price
- NNAVW N/A
- VCEL $60.60
- AVG Volume (30 Days)
- NNAVW 53.1K
- VCEL 811.4K
- Earning Date
- NNAVW 03-12-2025
- VCEL 11-06-2025
- Dividend Yield
- NNAVW N/A
- VCEL N/A
- EPS Growth
- NNAVW N/A
- VCEL 2045.40
- EPS
- NNAVW N/A
- VCEL 0.13
- Revenue
- NNAVW $4,963,000.00
- VCEL $249,119,000.00
- Revenue This Year
- NNAVW N/A
- VCEL $18.35
- Revenue Next Year
- NNAVW N/A
- VCEL $22.47
- P/E Ratio
- NNAVW N/A
- VCEL $224.93
- Revenue Growth
- NNAVW 43.44
- VCEL 16.13
- 52 Week Low
- NNAVW $4.47
- VCEL $29.94
- 52 Week High
- NNAVW $4.70
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- NNAVW N/A
- VCEL 35.84
- Support Level
- NNAVW N/A
- VCEL $30.26
- Resistance Level
- NNAVW N/A
- VCEL $33.25
- Average True Range (ATR)
- NNAVW 0.00
- VCEL 1.67
- MACD
- NNAVW 0.00
- VCEL -0.21
- Stochastic Oscillator
- NNAVW 0.00
- VCEL 1.31
About NNAVW NextNav Inc. Warrant
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.